208 related articles for article (PubMed ID: 27091805)
41. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum.
Salomon G; Maza A; Boulinguez S; Paul C; Lamant L; Tournier E; Mazereeuw-Hautier J; Meyer N
Br J Dermatol; 2018 May; 178(5):1199-1203. PubMed ID: 29274233
[TBL] [Abstract][Full Text] [Related]
42. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
Firwana B; Ravilla R; Raval M; Hutchins L; Mahmoud F
J Oncol Pharm Pract; 2017 Dec; 23(8):620-624. PubMed ID: 27590328
[TBL] [Abstract][Full Text] [Related]
43. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
[TBL] [Abstract][Full Text] [Related]
44. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
Woodbeck R; Metelitsa AI; Naert KA
Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
[TBL] [Abstract][Full Text] [Related]
45. Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti-PD-1.
Thomas S; Laino A; Sturm R; Nufer K; Lambie D; Shepherd B; Atkinson V; Adams L; Soyer HP; Schaider H
J Eur Acad Dermatol Venereol; 2018 May; 32(5):e176-e177. PubMed ID: 29114959
[No Abstract] [Full Text] [Related]
46. Severe Allograft Rejection and Autoimmune Hemolytic Anemia After Anti-PD1 Therapy in a Kidney Transplanted Patient.
Deltombe C; Garandeau C; Renaudin K; Hourmant M
Transplantation; 2017 Sep; 101(9):e291. PubMed ID: 29633980
[No Abstract] [Full Text] [Related]
47. Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma.
Quach HT; Dewan AK; Davis EJ; Ancell KK; Fan R; Ye F; Johnson DB
JAMA Oncol; 2019 Jun; 5(6):906-908. PubMed ID: 30998826
[TBL] [Abstract][Full Text] [Related]
48. [Toxic epidermal necrolysis due to anti-PD1 treatment with fatal outcome].
Demirtas S; El Aridi L; Acquitter M; Fleuret C; Plantin P
Ann Dermatol Venereol; 2017 Jan; 144(1):65-66. PubMed ID: 28011090
[No Abstract] [Full Text] [Related]
49. Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma.
Stuart L; Lambourne B; Turner P; Jones DEJ; Plummer R; Cresti N; Dyson JK
Hepatology; 2020 Jun; 71(6):2164-2166. PubMed ID: 31872447
[No Abstract] [Full Text] [Related]
50. Autoimmune Polyarthritis Induced by Cancer Immunotherapy With Checkpoint Inhibitor.
Quresh Q; Quinet R
J Clin Rheumatol; 2017 Jun; 23(4):235. PubMed ID: 28538282
[No Abstract] [Full Text] [Related]
51. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
52. Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab.
Cousin S; Toulmonde M; Kind M; Cazeau AL; Bechade D; Coindre JM; Italiano A
Ann Oncol; 2016 Jun; 27(6):1178-1179. PubMed ID: 27091806
[No Abstract] [Full Text] [Related]
53. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
54. Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies.
Bernard-Tessier A; Jeanville P; Champiat S; Lazarovici J; Voisin AL; Mateus C; Lambotte O; Annereau M; Michot JM
Eur J Cancer; 2017 Aug; 81():135-137. PubMed ID: 28624693
[No Abstract] [Full Text] [Related]
55. Hypothyroid ataxia complicating monoclonal antibody therapy.
Badran A; Moran C; Coles AJ
Pract Neurol; 2017 Dec; 17(6):482-484. PubMed ID: 28778931
[TBL] [Abstract][Full Text] [Related]
56. Durable response after cessation of anti-programmed death 1 therapy in four melanoma patients.
Handa T; Kato J; Sumikawa Y; Hida T; Horimoto K; Sato S; Sawada M; Fujioka M; Minowa T; Matsui Y; Uhara H
J Dermatol; 2019 Dec; 46(12):e461-e462. PubMed ID: 31583754
[No Abstract] [Full Text] [Related]
57. Autologous graft-versus-host disease with combined immune checkpoint blockade.
Kofler L; Dréno B; Röcken M
Eur J Cancer; 2018 Sep; 101():275-277. PubMed ID: 30017386
[No Abstract] [Full Text] [Related]
58. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.
Jespersen H; Bjursten S; Ny L; Levin M
Lancet Oncol; 2018 Jun; 19(6):e327. PubMed ID: 29893264
[No Abstract] [Full Text] [Related]
59. Melanoma: immune checkpoint blockade story gets better.
Bhatia S; Thompson JA
Lancet; 2014 Sep; 384(9948):1078-9. PubMed ID: 25034863
[No Abstract] [Full Text] [Related]
60. Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment.
Teyssonneau D; Cousin S; Italiano A
Ann Oncol; 2017 Dec; 28(12):3108. PubMed ID: 29045656
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
